Why Might You Need Pathology Review or Repeat Biomarker Testing in China?
Home > Blog > Travel & Hospital Navigation By MedBridgeNZ | Medical concierge and logistics coordination
Sources checked: 31 October 2026
You have the pathology and biomarker results. Now a cancer centre in China wants more work done. Does that mean the first diagnosis was wrong, or that you need another biopsy?
“Repeat testing” may mean reviewing existing slides, adding a test to stored tissue, repeating a previous test or taking a new sample. It does not necessarily mean the earlier diagnosis was wrong or that another biopsy is needed. The receiving team should explain what remains unclear and which appointment or care decision depends on the result.
What does “repeat testing” actually mean?
The request | What happens | Material that may be used |
Review existing pathology | A pathologist examines material from the earlier biopsy or surgery. | Existing stained slides; sometimes sections prepared from a stored block. |
Add a test | The laboratory performs a test that was not included in the earlier work. | Existing tissue, if enough suitable material remains. |
Repeat a previous test | The laboratory performs a test again for a reason the team should explain. | Existing material or a later sample, depending on the question. |
Obtain a new sample | A new biopsy or other sampling procedure collects material from you. | Newly collected tissue or cells. |
These steps can be combined. A request for new sections often means cutting more thin sections from a preserved paraffin block. That uses an existing specimen; it is not another biopsy. [1]
Why might a Chinese cancer centre request more work?
The request may involve one or more of these situations:
Review the original diagnosis. The Cancer Hospital, Chinese Academy of Medical Sciences, describes reviewing outside pathology after surgery elsewhere or on recurrence, as well as for difficult or disputed diagnoses. This describes that hospital’s service, not a rule for all centres; review does not mean the first diagnosis was wrong. [2]
Answer a different question. One biomarker test may check a single marker, another several. “Genetic testing” can also mean tumour testing or inherited cancer risk testing, which answer different questions. [3, 4]
Assess the available tissue. Too little tumour tissue can prevent biomarker testing; the receiving laboratory must assess whether stored material suits the proposed work. [3]
Look at a later point in the illness. Tumour biomarkers can change; after recurrence, doctors may consider testing again. A new test on tissue collected before later treatment still examines that earlier specimen. [3]
A separate biomarker report may also have been missed in the file transfer. Its absence does not establish that the test was never done. [1]
What should I ask before repeat biomarker testing in China?
These questions bring the discussion back to your own case:
What unanswered question will this review or test address?
What is new or being repeated compared with the tests already done?
Can my existing slides, block and complete reports be used? What is missing?
Which consultation or care decision needs the result, and who will explain the plan while we wait?
What is included in the estimate, when might results be ready, how will extra work be approved, and who will explain the findings?
Some answers must wait until the pathologist sees the material. MedBridgeNZ can organise documents and relay questions; clinicians decide which tests are needed.
Can the hospital use the reports and samples I already have?
Imagine sending the main surgical pathology report, only to discover later that the biomarker findings were issued as a separate report. NCI notes that findings from additional molecular tests may be reported separately. If the receiving hospital has only the first document, it may not yet have seen a result that already exists. [1]
The comparison becomes easier when each report is linked to the specimen it describes. Include the sample’s collection date and body site, and note any treatment since it was taken. If a previous test appears to overlap with the new request, the receiving team can compare the actual test names and findings, then explain what remains unresolved. You do not need to decide whether the assays are equivalent yourself.
Our guide to preparing reports, slides and blocks for a pathology review in China covers what to gather and how to check submission requirements. This article is about making sense of the work proposed after those records are reviewed.
Does the date of my earlier test matter?
When discussing repeat biomarker testing in China, start with the sample collection date, not just the report date. A report issued this month could describe a specimen collected before later treatment. Testing a stored block again may provide more detail about that specimen, but it cannot turn it into a sample from a later stage of the illness.
That distinction matters if the team wants to know whether the cancer’s biomarkers have changed. NCI explains that a past result may not reflect the tumour now and that a doctor may consider another test if the cancer returns. There is no universal number of months after which a report “expires”; the clinical question and available material matter. [3]
When might another biopsy be discussed?
Pathology review does not automatically lead to a new biopsy. A fresh sample may be discussed if the existing tissue cannot support the proposed test or if the team needs material collected after a change in the illness. Neither possibility, on its own, establishes that another procedure is right for you. [3]
If the hospital proposes new sampling, the treating team should explain what the new sample is intended to clarify, whether another route could answer the same question, how and where the sample would be taken, and the risks. The plan for your care while the result is pending also belongs in that conversation. Preparing new sections from an old block and obtaining new tissue from you are different arrangements.
What happens to appointments, costs and timing while results are pending?
Which appointment can go ahead?
“We need to wait for pathology” can refer to several different things. A pathologist may need an additional result before completing a report. An oncologist might be able to hold an initial discussion using the records already available, while leaving a later decision open. A procedure, admission or treatment booking may depend on the result. The receiving service can tell you which of these applies, and whether an appointment already booked should go ahead.
What is included in the estimate?
Costs may be staged too. Fudan University Shanghai Cancer Center’s published consultation information describes cases that require further sectioning, special stains, immunohistochemistry or molecular testing; it says additional special tests are charged separately. This is an example of why an initial consultation fee should not be taken as the total cost of every possible follow-on test. It is not a price or turnaround-time quote for your case. [5]
An itemised estimate is most useful when it separates the work agreed now from possible additions after review. It should identify the clinic or service, currency and date; any MedBridgeNZ coordination fee should be shown separately. If new work is proposed later, establish how its purpose and price will be explained and how your approval will be recorded. A newly proposed biopsy needs its own discussion of clinical implications and costs.
When will results be ready, and who will explain them?
For timing, find out when the estimate starts: when material arrives, when the laboratory accepts it as suitable, or when testing begins. Also identify who will update you if further work changes the expected date, and which clinician will discuss the result. An English report, a translation and a clinical discussion are separate arrangements. Our guide to what to confirm about English medical reports covers the delivery side.
Keep a short written record of the hospital’s answers: the agreed work, material to be used, the next decision awaiting results, estimated charges and timing, any approval still needed, and the contact for updates. Mark unanswered items as pending rather than treating them as agreed. This record helps the handover; it does not replace the hospital’s consent process.
Common questions about further testing
Does a second pathology opinion mean the first diagnosis was wrong?
No conclusion follows from the request alone. The receiving team may want to confirm the pathology before deciding what to do next. If the opinions differ, the pathologists and treating clinicians should explain what changed and whether it affects care.
Can I still have my first consultation before all the results are ready?
Possibly, but the receiving service needs to confirm what that appointment can cover and what remains open. An initial conversation and a final treatment decision may require different information.
Will another biomarker test necessarily identify a treatment?
No. NCI notes that testing may find no biomarker linked to an available treatment. Even when it finds a potential match, the treatment may not work for everyone. [3]
Help with the handover
If a Chinese hospital has requested further pathology or biomarker work, you can send MedBridgeNZ the wording of that request, the hospital or city you are considering, and a brief list of reports already in hand. You can share detailed records through an agreed channel after the initial enquiry.
We can help put reports in order, coordinate translation, relay your questions to the receiving team, and arrange agreed appointments and document handover. Testing decisions and interpretation of results remain with your clinicians.
MedBridgeNZ is an Auckland-based medical concierge and logistics coordinator. We do not provide medical advice, diagnosis or treatment.
References
National Cancer Institute. Pathology Reports.https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/pathology-reports-fact-sheet
Cancer Hospital, Chinese Academy of Medical Sciences. Pathology Consultation Centre: Introduction (中心介绍).https://www.cicams.ac.cn/dzb/pathology/bingli/zhong.html
National Cancer Institute. Biomarker Testing for Cancer Treatment.https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment
National Cancer Institute. Genetic Testing for Inherited Cancer Risk.https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet
Fudan University Shanghai Cancer Center. Pathology Consultation Information (病理会诊告知).https://www.shca.org.cn/Home/news/info/id/337/tid/312/fid/index.html
